购物车
您的购物车当前为空
KRAS G12D inhibitor 29 (Compound Formula (I)) 是一种口服活性和选择性的KRASG12D抑制剂,通过阻断KRASG12D介导的下游信号抑制肿瘤细胞增殖。KRAS G12D inhibitor 29 适用于研究与KRASG12D突变相关的癌症,包括胰腺癌、肺癌、结肠癌。

KRAS G12D inhibitor 29 (Compound Formula (I)) 是一种口服活性和选择性的KRASG12D抑制剂,通过阻断KRASG12D介导的下游信号抑制肿瘤细胞增殖。KRAS G12D inhibitor 29 适用于研究与KRASG12D突变相关的癌症,包括胰腺癌、肺癌、结肠癌。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 10-14周 | |
| 50 mg | 待询 | 10-14周 |
| 产品描述 | KRAS G12D inhibitor 29 (Compound Formula (I)) is an orally active and selective inhibitor of KRASG12D. It effectively blocks KRASG12D-mediated downstream signaling pathways, thereby inhibiting the proliferation of tumor cells. This compound holds potential for research into cancers associated with KRASG12D mutations, such as pancreatic cancer, lung cancer, and colorectal cancer. |
| 分子量 | 649.63 |
| 分子式 | C31H33F6N7O2 |
| CAS No. | 3018057-89-8 |
| Smiles | FC=1C2=C3C(N4[C@]([C@H](C)OC3=NC1C5=C(C(F)(F)F)C(C)=C(F)C(N)=C5)([C@]6(N[C@@](C4)(CC6)[H])[H])[H])=NC(OC[C@@]78N(C[C@H](F)C7)CCC8)=N2 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多